Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I bladder infusion trial of YH01 in BCG-unresponsive NMIBC
ChiCTR2500099871Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2025
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of YH01 in bladder cancer, Bladder cancer in situ (CIS) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose-limiting toxic events, Adverse events and 14 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
YH01
03
Conditions
bladder cancerBladder cancer in situ (CIS)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2500099871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099871.